Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

That's where CRISPR Therapeutics falls short. The company's approved product, Casgevy, is an ex vivo gene editing treatment.

Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

ARK Investment Management LLC, more commonly known as ARK Invest, is an American investment management firm headquartered in ...

The launch of Casgevy, CRISPR Therapeutics' gene therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), represents a significant milestone for the company.

The launch of Casgevy, CRISPR Therapeutics' gene therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), represents a significant milestone for the company. As of the ...

A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

Beth Mole, Ars Technica The First Crispr Treatment Is Making Its Way to Patients It’s been a year since the gene-editing ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...